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ABSTRACT: The enantiomers of the natural product
cycloprodigiosin were prepared using an expedient five-step
synthetic sequence that takes advantage of a Schöllkopf−
Barton−Zard (SBZ) pyrrole annulation with a chiral
isocyanoacetate and a nitrocyclohexene derivative. Using chiral
HPLC and X-ray crystallographic analyses of the synthetically
prepared material and natural isolate (isolated from the marine
bacterium Pseudoalteromonas rubra), naturally occurring cyclo-
prodigiosin was determined to be a scalemic mixture occurring in an enantiomeric ratio of 83:17 (R)/(S) at C4′.
The prodigiosins are an intriguing class of compounds(Figure 1) characterized by a tripyrrolic core and
remarkable bioactivity including anticancer, immunosuppres-
sive, and antiparasitic properties.1,2a−c Since the first reports of
their isolation in the 1960s, much effort has been expended in
exploring their biosynthesis, structure, and bioactivity.3a−c
There is continued interest in the study of the prodigiosins
because of their biological activity, which is believed to arise
principally from the binding of ions by the tripyrrolic
moiety4a−c as well as the interactions of these small molecules
with B-cell lymphoma 2 (Bcl-2) proteins.5 As recently advanced
by Thomson,6 it would appear that evolutionary selection of
the cyclic prodiginines has been such as to maximize the ability
of these molecules to bind ions and transport them across lipid
bilayers. These favorable bioactivities have led to the develop-
ment of a late-phase clinical candidate (Obatoclax) by Gemin
X.7,8 The exact mechanism of action for these molecules has yet
to be elucidated. Since 2 is chiral, the stereochemistry at C4′
should have implications in the ability of each enantiomer to
bind proteins, which may provide valuable insight into the
mechanism of action of these small molecules.
In this Letter, we demonstrate using total synthesis and
analysis of the natural isolate from Pseudoalteromonas rubra that
natural cycloprodigiosin occurs as a scalemic mixture (83:17,
(R)/(S)). Given the recent stereochemical elucidation of
streptorubin B (5) by Challis in 2011 as a scalemic mixture,
our finding suggests that the formation of 2 (analogous to the
production of 5) may involve a process (likely enzyme-
mediated) that proceeds with imperfect enantioselectivity.9
The unusual combination of lipophilic and hydrophilic
regions in the prodigiosins has not made their structural
characterization straightforward. Indeed, even with the
availability of modern analytical tools, a purported congener
of streptorubin B, butylcycloheptylprodigiosin, has only very
recently been correctly assigned.6 Overall, however, the
connectivity of the cyclic prodigiosins is now well established,
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Figure 1. Representative members in the prodigiosin family of
alkaloids.
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which has paved the way for clearer insight into their
biosynthesis.
The biosynthesis of several of the cyclic prodigiosins (e.g., 5
and 6) from their linear congener (4) has been shown to be
mediated by a notable class of Rieske nonheme iron dependent
oxygenases in Streptomyces spp.10a,b,3c,11 The biosynthesis of
cycloprodigiosin (2), first isolated from the marine bacterium P.
rubra, presumably proceeds by cyclization of its linear congener
prodigiosin (1). However, this hypothesis remains unsub-
stantiated. Additionally, while the constitution of cyclo-
prodigiosin has been secured through careful analysis and
total synthesis,12a,b,13 it remains unknown whether cyclo-
prodigiosin occurs in a racemic, scalemic, or enantiopure
form. Insight into the nature of the existing stereocenter in 2
could have a significant impact on the understanding of its
biogenesis as well as its mode of biological action.
A particularly intriguing feature of the cyclic prodigiosins is
that naturally occurring streptorubin B is a scalemic mixture
(95:5) at C7′ (see Figure 2) favoring the S enantiomer as
established through studies by Challis and Thomson.9,14,15
Strikingly, the predominant isomer of natural metacyclo-
prodigiosin is 9′R; however whether 6 also occurs as a scalemic
mixture has not been rigorously established.10a As a result, the
stereochemistry at C4′ of 2 cannot be presumed by analogy to
the other existing cyclic prodiginines. We sought to establish
the absolute stereochemistry and enantiopurity of 2 through a
comparison of synthetic material to the natural isolate.10c,16
Even though prior syntheses of 2 have been reported,13,17 it
was our goal to develop an efficient and scalable synthesis that
would afford either enantiomer of 2 to facilitate our planned
studies into the stereochemical assignment. Given the lack of
information regarding the stereoconfiguration of the natural
isolate of 2, we designed a synthetic route that would provide
access to the racemate as well as each enantiomer.
As shown in Scheme 1, we envisioned 2 arising from
condensation of fused pyrrole 7 and bis-pyrrole aldehyde 8
following the well-established precedent of Wasserman using
HCl.13 Key to this coupling would be an initial saponification/
decarboxylation of the ester group of 7. Fused pyrrole 7 could
in turn be prepared from the two-component coupling of cyclic
nitroalkene 9 and isocyanoacetates of general structure 10 using
a Schöllkopf−Barton−Zard (SBZ) pyrrole synthesis.18 In order
to access both enantiomers of cycloprodigiosin, we planned to
use a chiral auxiliary on the carboxy group of 10 (R = auxiliary)
to facilitate separation of the diastereomers of 7 at a later stage
in the synthesis.
The synthesis of racemic 2 commenced with the preparation
of 3-methyl-1-nitrocyclohexene (9; see Scheme 2), which was
obtained from 3-methylcyclohexene in one step according to
the procedure of Estreicher and Corey.19 Subjecting 9 to ethyl
isocyanoacetate (11) effected an SBZ pyrrole annulation18 to
afford 12 in 67% yield. Several methods were then explored for
installation of a methyl group at the pyrrole C5 position.
Envisioning rapid access to methylated pyrrole 15, we first
investigated a method recently developed by Baran and co-
workers.20 Thus, treatment of pyrrole 12 with zinc bis[(phenyl-
sulfonyl)methanesulfinate] (PSMS; 13) and tert-butylhydro-
peroxide (TBHP) afforded methylenesulfone adduct 14 (56%
yield), which upon treatment with freshly prepared samarium
iodide was reduced to the desired C5 methylated pyrrole (15)
in 69% yield. While this method provided efficient access to 15,
in our hands, an alternative approach proved to be more
serviceable and cost-effective.
In this alternative sequence (Scheme 3), pyrrole 12 was
brominated at C5 in 75% yield using NBS, which provided 16
in preparation for cross-coupling with a methyl group
equivalent. As reported by Neumann and co-workers,21 the
coupling efficiency was significantly higher upon Boc-
protection of the pyrrole nitrogen (to give 17). A survey of
Pd-catalyzed cross-coupling partners revealed that tetramethyl-
tin serves as the most reliable coupling partner to provide a
mixture of 18 and the deprotected analogue (15) in a
combined 58% yield from 17. Notably, the formation of both
15 and 18 is inconsequential as each compound serves as a
substrate in the final condensation to form cycloprodigiosin. In
the event, subjection of a mixture of 15 and 18 to NaOH in
ethylene glycol at 210 °C (to effect a saponification/
decarboxylation sequence) followed by the introduction of 8
yields racemic cycloprodigiosin·HCl (2·HCl) in 72% yield.22
Scheme 1. Retrosynthetic Plan Highlighting a Two-
Component SBZ Pyrrole Annulation
Scheme 2. Methylation Sequence Using Baran’s PSMS
Reagent (13)20
Scheme 3. Alternative Methylation Sequence Utilizing
Brominated Pyrrole (17) as a Coupling Partner
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This synthetic sequence also provided the basis for the
preparation of enantioenriched cycloprodigiosin using
(−)-menthol-derived isocyanoacetate 19 (Scheme 4; prepared
according to the procedure of Verkade)23 in place of ethyl
isocyanoacetate in the SBZ pyrrole annulation. The enan-
tiomers of cycloprodigiosin ((S)-2·HCl and (R)-2·HCl) were
prepared with similar efficiencies as described for the racemic
case by advancing diastereomers 20 and 21 separately (see the
Supporting Information for more details). X-ray crystallo-
graphic analysis of the HCl salt of enantiomer (R)-2·HCl has
enabled absolute stereochemical characterization of the
materials that we have prepared, which has set the stage for
analysis of the natural material.
A sample of naturally occurring cycloprodigiosin was
obtained from P. rubra (Gauthier 1976, ATCC 29570) (see
the Supporting Information for details) and purified by
sequential normal and reversed-phase chromatography. In
total, 0.2 mg of the natural product was obtained from 1 L of
culture. With the natural isolate of cycloprodigiosin (from P.
rubra) as well as our synthetic material in hand, we analyzed
these materials using HPLC (Chiralpak IA) monitoring the
absorbance at 500 nm.12b,24 Comparison of the HPLC trace of
the natural isolate to those of the racemic and enantiopure
((S)-2 and (R)-2) material prepared by us is shown in Figure 2.
(R)-2 has a retention time of ∼5.43 min (Figure 2c) whereas
(S)-2 has a retention time of ∼10.02 min (Figure 2d). These
observations are corroborated by our observations for racemic
cycloprodigiosin (Figure 2a). The natural isolate displays two
peaks that correspond to the two enantiomers in the ratio
83:17 for (R)-2/(S)-2 (Figure 2b). Two independent
production experiments gave identical enantiomeric ratios.
Thus, it would appear that naturally occurring 2 is scalemic.
These observations are consistent with those of Challis et al. for
streptorubin B, albeit occurring with markedly lower
enantiopurity in the case of cycloprodigiosin.
In conclusion, we report a rapid and novel synthesis of
cycloprodigiosin that is easily modified to afford both
enantiomers of the natural product. We have also achieved
the growth and isolation of cycloprodigiosin from P. rubra. Our
analyses of these materials using a combination of X-ray
crystallography and chiral HPLC have revealed that naturally
occurring cycloprodigiosin obtained from P. rubra occurs as a
scalemic mixture, which is analogous to observations made
previously for streptorubin B. These observations should have
implications in terms of our understanding of the biosynthesis
of cycloprodigiosin in P. rubra; biochemical studies are
currently ongoing in our laboratory. Furthermore, these studies
will inform investigations into the bioactivity of cyclo-
prodigiosin, specifically in terms of the interactions of each
enantiomer with biomolecules.
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